Prognose

Das durchschnittliche Kursziel der Analysten beträgt +17,20€(+76,41%). Der Median liegt bei +17,20€(+76,41%).

Kaufen	5
Halten	3
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	9 / 18
Levermann-Strategie	-5 / 13

News

Smartkem Announces Preliminary Joint Development Agreement with Manz Asia for Advanced Computer and AI Chip Packaging Solutions
Joint Development Agreement builds on ongoing collaboration with Manz Asia MANCHESTER, England , July 9, 2025 /PRNewswire/ -- Smartkem (Nasdaq: SMTK), which is seeking to change the world of electronics with a new class of transistor technology, today announced that it has entered into a preliminary Joint Development Agreement (JDA) with Manz Asia, a pioneer in advanced packaging equipment for the semiconductor industry, which, when finalized will focus on the co-development of next generation dielectric ink solutions for advanced packaging manufacturing, particularly tailored for AI chip packaging applications. Smartkem Chairman and CEO, Ian Jenks, comments: "This joint development agreement builds on our collaboration with Manz Asia which has already resulted in our first demonstration at SEMICON® SEA 2025 of an advanced inkjet metalization process for packaging chips for production.» Mehr auf prnewswire.com
Toll Brothers Apartment Living® and International Capital, LLC Announce Joint Venture to Develop 348-Unit Luxury Multifamily Community in Charlotte
JV secures $56.8 million construction loan from TD Bank for The Airedale, Toll Brothers Apartment Living's first multifamily community in North Carolina JV secures $56.8 million construction loan from TD Bank for The Airedale, Toll Brothers Apartment Living's first multifamily community in North Carolina» Mehr auf globenewswire.com
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that an access and benefit sharing agreement focused on two cultivated species of the coca plant - Erythroxylum coca and Erythroxylum novogranatense - from Peru has been signed between Peru's National Institute of Agrarian Innovation (INIA) and Psilo Scientific, a subsidiary of Filament Health Corp. (OTC:FLHLF) ("Filament"). The access agreement authorizes the research program of Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Filament, into a variety of potential mental health and central nervous system (CNS) indications for coca.» Mehr auf accessnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Joint Co. einen Umsatz von 12,09 Mio€ und ein Nettoeinkommen von 740,81k€

(EUR)	März 2025	YOY
Umsatz	+12,09 Mio	56,11%
Bruttoeinkommen	+9,73 Mio	58,98%
Nettoeinkommen	+740,81k	15,57%
EBITDA	+1,09 Mio	58,90%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+150,91 Mio€
Anzahl Aktien	15,30 Mio
52 Wochen-Hoch/Tief	+13,17€ - +8,24€
Dividenden	Nein
Beta	1,49
KGV (PE Ratio)	−20,08
KGWV (PEG Ratio)	+11,44
KBV (PB Ratio)	+8,74
KUV (PS Ratio)	+4,98

Unternehmensprofil

The Joint Corp. entwickelt, besitzt, betreibt, unterstützt und verwaltet chiropraktische Kliniken. Das Unternehmen ist in zwei Segmenten tätig: Corporate Clinics und Franchise Operations. Das Unternehmen ist durch Direktbesitz, Managementvereinbarungen, Franchising und regionale Entwickler tätig. Zum 1. März 2022 betrieb das Unternehmen rund 700 Standorte in den Vereinigten Staaten. The Joint Corp. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Scottsdale, Arizona.